Puma Biotechnology Expands Neratinib Access to HER2+ Breast Cancer Patients Ineligible for Clinical Trials
News
Women with HER2-positive breast cancer or HER-mutated cancers who cannot participate in any PB272 (neratinib) clinical trial may now receive the investigational drug under the expanded access program (EAP) initiated by Los Angeles-based Puma ... Read more